{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:54:41Z","timestamp":1790999681313,"version":"4.1.0"},"reference-count":73,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.1248\/bpb.b26-00232","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:12:44Z","timestamp":1790806364000},"page":"1579-1586","source":"Crossref","is-referenced-by-count":0,"title":["Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics"],"prefix":"10.1248","volume":"49","author":[{"given":"Shota","family":"Ichimizu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"},{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Tsukuba Hospital, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"},{"name":"Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Peters T. <i>All about albumin: biochemistry, genetics, and medical applications<\/i>. Academic Press Inc., San Diego (1996)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Otagiri M, Chuang VTG. <i>Albumin in Medicine: pathological and Clinical Applications<\/i>. Springer, Singapore (2016).","DOI":"10.1007\/978-981-10-2116-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. <i>J. Biol. Chem.<\/i>, <b>275<\/b>, 38731\u201338738 (2000).","DOI":"10.1074\/jbc.M005460200"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Anraku M, Chuang VT, Maruyama T, Otagiri M. Redox properties of serum albumin. <i>Biochim. Biophys. Acta, Gen. Subj.<\/i>, <b>1830<\/b>, 5465\u20135472 (2013).","DOI":"10.1016\/j.bbagen.2013.04.036"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Watanabe H, Imafuku T, Otagiri M, Maruyama T. Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases. <i>J. Pharm. Sci.<\/i>, <b>106<\/b>, 2195\u20132203 (2017).","DOI":"10.1016\/j.xphs.2017.03.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Belinskaia DA, Jenkins RO, Goncharov NV. Albumin is an integrative protein of blood plasma and beyond. <i>Int. J. Mol. Sci.<\/i>, <b>25<\/b>, 12627 (2024).","DOI":"10.3390\/ijms252312627"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shevtsova A, Gordiienko I, Tkachenko V, Ushakova G. Ischemia-modified albumin: origins and clinical implications. <i>Dis. Markers<\/i>, <b> 2021<\/b>, 9945424 (2021).","DOI":"10.1155\/2021\/9945424"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Cl\u00e0ria J, Stauber RE, Coenraad MJ, <i>et al<\/i>. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. <i>Hepatology<\/i>, <b>64<\/b>, 1249\u20131264 (2016).","DOI":"10.1002\/hep.28740"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Di Bona D, Scapagnini G, Candore G, Castiglia L, Colonna-Romano G, Duro G, Nuzzo D, Iemolo F, Lio D, Pellican\u00f2 M, Scafidi V, Caruso C, Vasto S. Immune-inflammatory responses and oxidative stress in Alzheimer\u2019s disease: therapeutic implications. <i>Curr. Pharm. Des.<\/i>, <b>16<\/b>, 684\u2013691 (2010) \u2039https:\/\/www.benthamdirect.com\/content\/journals\/cpd\/10.2174\/138161210790883769\u203a.","DOI":"10.2174\/138161210790883769"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. <i>Cardiovasc. Ther.<\/i>, <b>30<\/b>, 49\u201359 (2012).","DOI":"10.1111\/j.1755-5922.2010.00218.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ma X, Lin Y, Zhang L, Huang Z, Zhang Y, Fu X, Li P. The dual missions of FoxO3a in inflammatory diseases: regulation of antioxidant enzymes and involvement in programmed cell death. <i>Int. Immunopharmacol.<\/i>, <b>151<\/b>, 114369 (2025).","DOI":"10.1016\/j.intimp.2025.114369"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F, Mao Z. The emerging role of oxidative stress in inflammatory bowel disease. <i>Front. Endocrinol.<\/i>, <b>15<\/b>, 1390351 (2024).","DOI":"10.3389\/fendo.2024.1390351"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E, Cerretani D. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. <i>Curr. Vasc. Pharmacol.<\/i>, <b>13<\/b>, 26\u201336 (2015).","DOI":"10.2174\/15701611113119990003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Traten\u0161ek A, Locatelli I, Grabnar I, Drobne D, Vovk T. Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: a systematic review and meta-analysis. <i>Redox Biol.<\/i>, <b>77<\/b>, 103380 (2024).","DOI":"10.1016\/j.redox.2024.103380"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Franken LG, Masman AD, de Winter BCM, Baar FPM, Tibboel D, van Gelder T, Koch BCP, Mathot RAA. Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? <i>Br. J. Clin. Pharmacol.<\/i>, <b>83<\/b>, 1701\u20131712 (2017).","DOI":"10.1111\/bcp.13259"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kumar W, Martins RS, Anjum N, Fatima SS. Ischemia modified albumin as a useful marker for diagnoses and management of diabetic retinopathy. <i>Pak. J. Med. Sci.<\/i>, <b>38<\/b> (4Part-II), 1043\u20131047 (2022).","DOI":"10.12669\/pjms.38.4.4813"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, Erduran E. Ischemia-modified albumin levels in children with chronic liver disease. <i>Gut Liver<\/i>, <b>6<\/b>, 92\u201397 (2012).","DOI":"10.5009\/gnl.2012.6.1.92"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kumar PA, Subramanian K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. <i>J. Clin. Diagn. Res.<\/i>, <b>10<\/b>, BC09\u2013BC12 (2016).","DOI":"10.7860\/JCDR\/2016\/17168.7399"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Balta S, Alemdar R, Erdogan S, Demir M, Ozturk C, Celik T. Ischemia modified albumin in cardiovascular disease. <i>Am. J. Emerg. Med.<\/i>, <b>34<\/b>, 1699 (2016).","DOI":"10.1016\/j.ajem.2016.05.030"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. <i>Int. J. Pept. Protein Res.<\/i>, <b>24<\/b>, 96\u2013103 (1984).","DOI":"10.1111\/j.1399-3011.1984.tb00933.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Turell L, Botti H, Carballal S, Ferrer-Sueta G, Souza JM, Dur\u00e1n R, Freeman BA, Radi R, Alvarez B. Reactivity of sulfenic acid in human serum albumin. <i>Biochemistry<\/i>, <b>47<\/b>, 358\u2013367 (2008).","DOI":"10.1021\/bi701520y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, Suenaga A, Otagiri M. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). <i>Drug Metab. Pharmacokinet.<\/i>, <b>21<\/b>, 140\u2013146 (2006).","DOI":"10.2133\/dmpk.21.140"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Baraka-Vidot J, Guerin-Dubourg A, Bourdon E, Rondeau P. Impaired drug-binding capacities of <i>in vitro<\/i> and <i>in vivo<\/i> glycated albumin. <i>Biochimie<\/i>, <b>94<\/b>, 1960\u20131967 (2012).","DOI":"10.1016\/j.biochi.2012.05.017"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. <i>Diabetes<\/i>, <b>54<\/b>, 1615\u20131625 (2005).","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. <i>Diabetes<\/i>, <b>57<\/b>, 1446\u20131454 (2008).","DOI":"10.2337\/db08-0057"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Imafuku T, Watanabe H, Oniki K, <i>et al<\/i>. Cysteinylated albumin as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes. <i>Diabetes Care<\/i>, <b>44<\/b>, e115\u2013e117 (2021).","DOI":"10.2337\/dc20-3003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Brioschi M, Gianazza E, Mallia A, Zoanni B, Altomare A, Martinez Fernandez A, Agostoni P, Aldini G, Banfi C. S-thiolation targets albumin in heart failure. <i>Antioxidants<\/i>, <b>9<\/b>, 763 (2020).","DOI":"10.3390\/antiox9080763"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Zoanni B, Brioschi M, Mallia A, Gianazza E, Eligini S, Carini M, Aldini G, Banfi C. Novel insights about albumin in cardiovascular diseases: focus on heart failure. <i>Mass Spectrom. Rev.<\/i>, <b>42<\/b>, 1113\u20131128 (2023).","DOI":"10.1002\/mas.21743"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, Nagano J, Ko T, Mera K, Tomita K, Otagiri M. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. <i>Clin. Biochem.<\/i>, <b>41<\/b>, 1168\u20131174 (2008).","DOI":"10.1016\/j.clinbiochem.2008.07.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. <i>PLOS ONE<\/i>, <b>9<\/b>, e85216 (2014).","DOI":"10.1371\/journal.pone.0085216"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, Putz-Bankuti C, Krisper P, Graziadei I, Vogel W, Lackner C, Stauber RE. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. <i>J. Hepatol.<\/i>, <b>59<\/b>, 978\u2013983 (2013).","DOI":"10.1016\/j.jhep.2013.06.013"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kato H, Watanabe H, Imafuku T, Arimura N, Fujita I, Noguchi I, Tanaka S, Nakano T, Tokumaru K, Enoki Y, Maeda H, Hino S, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress <i>via<\/i> CD36\/NADPH oxidase pathway. <i>J. Cachexia Sarcopenia Muscle<\/i>, <b>12<\/b>, 1832\u20131847 (2021).","DOI":"10.1002\/jcsm.12786"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Costa M, Horrillo R, Ortiz AM, P\u00e9rez A, Mestre A, Ruiz A, Boada M, Grancha S. Increased albumin oxidation in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients. <i>J. Alzheimers Dis.<\/i>, <b>63<\/b>, 1395\u20131404 (2018).","DOI":"10.3233\/JAD-180243"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Brahma D, Sarangi AN, Kaushik R, Gupta AN. Oxidative stress induced conformational changes of human serum albumin. <i>Phys. Chem. Chem. Phys.<\/i>, <b>26<\/b>, 8528\u20138538 (2024).","DOI":"10.1039\/D4CP00059E"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. <i>Front. Immunol.<\/i>, <b>5<\/b>, 682 (2014).","DOI":"10.3389\/fimmu.2014.00682"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Leblanc Y, Berger M, Seifert A, Bihoreau N, Chevreux G. Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions. <i>Protein Sci.<\/i>, <b>28<\/b>, 1982\u20131992 (2019).","DOI":"10.1002\/pro.3733"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. <i>JPEN J. Parenter. Enteral Nutr.<\/i>, <b>43<\/b>, 181\u2013193 (2019).","DOI":"10.1002\/jpen.1451"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Riddles PW, Blakeley RL, Zerner B. Ellman\u2019s reagent: 5,5\u2032-dithiobis(2-nitrobenzoic acid)\u2014a reexamination. <i>Anal. Biochem.<\/i>, <b>94<\/b>, 75\u201381 (1979).","DOI":"10.1016\/0003-2697(79)90792-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Anraku M, Takeuchi K, Watanabe H, Kadowaki D, Kitamura K, Tomita K, Kuniyasu A, Suenaga A, Maruyama T, Otagiri M. Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. <i>J. Pharm. Sci.<\/i>, <b>100<\/b>, 3968\u20133976 (2011).","DOI":"10.1002\/jps.22571"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Bal W, Soko\u0142owska M, Kurowska E, Faller P. Binding of transition metal ions to albumin: sites, affinities and rates. <i>Biochim. Biophys. Acta, Gen. Subj.<\/i>, <b>1830<\/b>, 5444\u20135455 (2013).","DOI":"10.1016\/j.bbagen.2013.06.018"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Lee P, Wu X. Review: modifications of human serum albumin and their binding effect. <i>Curr. Pharm. Des.<\/i>, <b>21<\/b>, 1862\u20131865 (2015).","DOI":"10.2174\/1381612821666150302115025"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Levine RL. Ischemia: from acidosis to oxidation. <i>FASEB J.<\/i>, <b>7<\/b>, 1242\u20131246 (1993).","DOI":"10.1096\/fasebj.7.13.8405809"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. <i>Heart<\/i>, <b>92<\/b>, 113\u2013114 (2006).","DOI":"10.1136\/hrt.2004.049643"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. <i>Eur. J. Biochem.<\/i>, <b>227<\/b>, 524\u2013528 (1995).","DOI":"10.1111\/j.1432-1033.1995.tb20419.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical utility and pitfalls in measurement. <i>J. Clin. Pathol.<\/i>, <b>61<\/b>, 1025\u20131028 (2008).","DOI":"10.1136\/jcp.2007.053363"},{"key":"46","unstructured":"46) Gaze DC. <i>\u2018Biomarkers of Cardiac Ischemia\u2019. Ischemic Heart Disease<\/i>. InTech., London (2013) \u2039https:\/\/www.intechopen.com\/chapters\/42794\u203a."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. <i>Clin. Chem.<\/i>, <b>49<\/b>, 581\u2013585 (2003).","DOI":"10.1373\/49.4.581"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Sinha MK, Vazquez JM, Calvino R, Gaze DC, Collinson PO, Kaski JC. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. <i>Heart<\/i>, <b>92<\/b>, 1852\u20131853 (2006).","DOI":"10.1136\/hrt.2005.078089"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Abusoglu S, Eryavuz D, Bal C, Nural C, Ozcan E, Yildirimel M, Celik S, Unlu A. Assessment of serum ischemia-modified albumin, Prolidase and thiol-disulphide levels in subjects with breast cancer. <i>Rev. Rom. Med. Lab.<\/i>, <b>27<\/b>, 25\u201333 (2019).","DOI":"10.2478\/rrlm-2019-0013"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. <i>Biomarkers<\/i>, <b>15<\/b>, 655\u2013662 (2010).","DOI":"10.3109\/1354750X.2010.513449"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of \u201cIschemia modified albumin\u201d, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. <i>Emerg. Med. J.<\/i>, <b>21<\/b>, 29\u201334 (2004).","DOI":"10.1136\/emj.2003.006007"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Antman E, Bassand JP, Klein W, Ohman M, Sendon JLL, Ryd\u00e9n L, Simoons M, Tendera M. Myocardial infarction redefined\u2014a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. <i>J. Am. Coll. Cardiol.<\/i>, <b>36<\/b>, 959\u2013969 (2000).","DOI":"10.1016\/S0735-1097(00)00804-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H. It\u2019s time for a change to a troponin standard. <i>Circulation<\/i>, <b>102<\/b>, 1216\u20131220 (2000).","DOI":"10.1161\/01.CIR.102.11.1216"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy. <i>Biomark. Insights<\/i>, <b>11<\/b>, BMI.S39053 (2016).","DOI":"10.4137\/BMI.S39053"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Ding M, Li M, Yang H. Clinical diagnostic value of combined detection of IMA, D-D and MCP-1 in acute myocardial infarction. <i>Exp. Ther. Med.<\/i>, <b>21<\/b>, 457 (2021).","DOI":"10.3892\/etm.2021.9888"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Bilgi M, Keser A, Katlandur H, Sahin E, Kalkan AO, Yildiz M, Kiyici A, Keles M. Evaluation of the relationship between microalbuminuria and urine ischemia-modified albumin levels in patients with diabetic nephropathy. <i>J. Clin. Lab. Anal.<\/i>, <b>31<\/b>, e22058 (2017).","DOI":"10.1002\/jcla.22058"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) \u017bebrowska A, Wa\u015bkiewicz Z, Nikolaidis PT, Miko\u0142ajczyk R, Kawecki D, Rosemann T, Knechtle B. Acute responses of novel cardiac biomarkers to a 24-h ultra-marathon. <i>J. Clin. Med.<\/i>, <b>8<\/b>, 57 (2019).","DOI":"10.3390\/jcm8010057"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Storz P. Oxidative Stress in Cancer. <i>Oxidative Stress and Redox Regulation<\/i>. (Jakob U, Reichmann D, ed.) Springer, Netherlands, pp. 427\u2013447 (2013).","DOI":"10.1007\/978-94-007-5787-5_15"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Kundaktepe BP, Sozer V, Durmus S, Kocael PC, Kundaktepe FO, Papila C, Gelisgen R, Uzun H. The evaluation of oxidative stress parameters in breast and colon cancer. <i>Medicine<\/i>, <b>100<\/b>, e25104 (2021).","DOI":"10.1097\/MD.0000000000025104"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, Williams R, Matthes G, Davies NA. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. <i>Hepatology<\/i>, <b>50<\/b>, 555\u2013564 (2009).","DOI":"10.1002\/hep.22913"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Sakurama K, Nishi K, Chuang VTG, Hashimoto M, Yamasaki K, Otagiri M. Effects of oxidation of human serum albumin on the binding of aripiprazole. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1023\u20131026 (2020).","DOI":"10.1248\/bpb.b20-00205"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Sakurama K, Kawai A, Chuang VTG, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M. Analysis of the binding of aripiprazole to human serum albumin: the importance of a chloro-group in the chemical structure. <i>ACS Omega<\/i>, <b>3<\/b>, 13790\u201313797 (2018).","DOI":"10.1021\/acsomega.8b02057"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Sakurama K, Nishi K, Imoto S, Hashimoto M, Komatsu T, Morita Y, Taguchi K, Otagiri M, Yamasaki K. Further evidence regarding the important role of chlorine atoms of aripiprazole on binding to the site II area of human albumin. <i>J. Pharm. Sci.<\/i>, <b>108<\/b>, 1890\u20131895 (2019).","DOI":"10.1016\/j.xphs.2018.11.045"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M. Effect of oxidative stress on the structure and function of human serum albumin. <i>Pharm. Res.<\/i>, <b>18<\/b>, 632\u2013639 (2001).","DOI":"10.1023\/A:1011029226072"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Iwao Y, Anraku M, Yamasaki K, Kragh-Hansen U, Kawai K, Maruyama T, Otagiri M. Oxidation of Arg-410 promotes the elimination of human serum albumin. <i>Biochim. Biophys. Acta. Proteins Proteom.<\/i>, <b>1764<\/b>, 743\u2013749 (2006).","DOI":"10.1016\/j.bbapap.2006.01.011"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, Otagiri M. Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity. <i>Biochem. J.<\/i>, <b>349<\/b>, 813\u2013819 (2000).","DOI":"10.1042\/bj3490813"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Maci\u0105\u017cek-Jurczyk M, Su\u0142kowska A, R\u00f3wnicka-Zubik J. Alteration of methotrexate binding to human serum albumin induced by oxidative stress. Spectroscopic comparative study. <i>Spectrochim. Acta A Mol. Biomol. Spectrosc.<\/i>, <b>152<\/b>, 537\u2013550 (2016).","DOI":"10.1016\/j.saa.2014.12.113"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress <i>via<\/i> neutrophil burst. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>334<\/b>, 1322\u20131328 (2005).","DOI":"10.1016\/j.bbrc.2005.07.035"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Paar M, Fengler VH, Rosenberg DJ, Krebs A, Stauber RE, Oettl K, Hammel M. Albumin in patients with liver disease shows an altered conformation. <i>Commun. Biol.<\/i>, <b>4<\/b>, 731 (2021).","DOI":"10.1038\/s42003-021-02269-w"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. <i>J. Am. Coll. Cardiol.<\/i>, <b>71<\/b>, 2162\u20132175 (2018).","DOI":"10.1016\/j.jacc.2018.03.023"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Ichimizu S, Watanabe H, Maeda H, Hamasaki K, Nakamura Y, Chuang VTG, Kinoshita R, Nishida K, Tanaka R, Enoki Y, Ishima Y, Kuniyasu A, Kobashigawa Y, Morioka H, Futaki S, Otagiri M, Maruyama T. Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery. <i>J. Control. Release<\/i>, <b>277<\/b>, 23\u201334 (2018).","DOI":"10.1016\/j.jconrel.2018.02.037"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Ichimizu S, Watanabe H, Maeda H, Hamasaki K, Ikegami K, Chuang VTG, Kinoshita R, Nishida K, Shimizu T, Ishima Y, Ishida T, Seki T, Katsuki H, Futaki S, Otagiri M, Maruyama T. Cell-penetrating mechanism of intracellular targeting albumin: contribution of macropinocytosis induction and endosomal escape. <i>J. Control. Release<\/i>, <b>304<\/b>, 156\u2013163 (2019).","DOI":"10.1016\/j.jconrel.2019.05.015"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Maeda H, Ichimizu S, Watanabe H, Hamasaki K, Chikamatsu M, Murata R, Yumoto N, Seki T, Katsuki H, Otagiri M, Maruyama T. Cell-penetrating albumin enhances the sublingual delivery of antigens through macropinocytosis. <i>Int. J. Biol. Macromol.<\/i>, <b>221<\/b>, 1439\u20131452 (2022).","DOI":"10.1016\/j.ijbiomac.2022.09.132"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00232\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:25:50Z","timestamp":1790997950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00232\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00232","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"b26-00232"}}